Instructions for Diartrin (Diacerein) 30 capsules 50 mg
English product name
Diartrin
Release form:
Capsules
Description:
Capsules are solid gelatine, size №1, with body and cap in yellow;
The capsule contents are yellow powder.
diacerein 50 mg
Auxiliary substances:
- cornstarch - 30 mg,
- lactose monohydrate - 188.95 mg,
- silicon dioxide colloidal - 1.5 mg,
- povidone K-30 - 2.2 mg,
- crossovidone (type A) - 24 mg,
- sodium lauryl sulfate - 0.35 mg,
- magnesium stearate - 3 mg.
- titanium dioxide - 1.3333%,
- quinoline yellow dye - 0.9197%,
- sun sunset yellow dye - 0.0044%,
- gelatin - up to 100%.
10 pcs - box-type contour (3) packages - cardboard packs.
ATC codes
M01AX21 Diacerein
Clinical-pharmacological groups / Group affiliation
Preparation for inflammatory and inflammatory dystrophic diseases of the musculoskeletal system
Active substance
diacerein
Pharmacotherapy group
NSAIDs
Storage Conditions
The drug should be stored in a place inaccessible to children, dry, protected from light at a temperature not higher than 25 ° C.
Best before date
The shelf life is two years. Do not apply after the expiry date indicated on the package.
Testimony:
- Symptomatic treatment of osteoarthrosis of hip and knee joints.
Method of use, course and dosage:
Inside, after eating, swallowing whole, water, 50 mg (one capsule) twice/day (morning and evening).
Treatment is carried out continuously for a long time or for courses of at least four months.
Since diacerein during the first two weeks can cause an acceleration of transit in the gut, it is recommended to start treatment with one capsule per day (in the evening, during meals) within four weeks. After consultation with the doctor, the dose can then be increased to 10mg (two capsules/day).
In patients with moderate-severity renal failure (CC 30-60 ml/min), the dose of the drug should be reduced by half to fifty mg (one capsule per day).
Application for kidney disorders
The use of the preparation in case of severe renal insufficiency (QC of less than 30 ml/min) is contraindicated.
In patients with moderate-severity renal failure (MMR thirty to sixty ml/min), the dose of the drug should be reduced by half.
Application for kidney disorders
The use of the preparation in case of severe renal insufficiency (QC of less than 30 ml/min) is contraindicated.
In patients with moderate-severity renal failure (MMR thirty to sixty ml/min), the dose of the drug should be reduced by half.
Use in liver disorders
The use of the preparation in patients with liver diseases (including anamnesis) is contraindicated.
Terms of Sale
The drug is prescription.
Application in elderly patients
With caution: patients aged 65 and over.
Use in children
The use of the preparation in the age of up to 18 years is contraindicated.
- Nosology (ICD codes)
- M16
- Coxarthrosis
- hip arthrosis]
- M17
- Gonarthrosis [knee arthrosis]
Pharmacological effect:
Diacerein is a derivative of anthraquinoline, a diacetylated derivative of reine.
It is metabolized to the active metabolite of reine, inhibiting interleukin-1 activity, which plays an important role in the development of inflammation and cartilage degradation in osteoarthrosis.
Diacerein inhibits the action of other cytokines including interleukin-6, the tumor necrosis factor-α. The action takes two to
four weeks.
Diacerein has analgesic and anti-inflammatory activity when taken in.
